Wednesday, July 8, 2026

Patent intelligence · US

US 10711007

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

granted A61PA61P35/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 16
Patent details — US 10711007

Quick answer

US 10711007 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jul 14, 2020. Expires Jul 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
26
CPC classes
A61P, A61P35/00

More from Prelude Therapeutics, Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12414953

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Expires Sep 11, 2045

    granted
  2. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Expires Oct 24, 2044

    granted
  3. US 11939340

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Expires Mar 21, 2044

    granted
  4. US 11702423

    BRM targeting compounds and associated methods of use

    Prelude Therapeutics, Incorporated · Expires Jul 13, 2043

    granted
  5. US 11685744

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Expires Jun 22, 2043

    granted
  6. US 11673893

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Expires Jun 8, 2043

    granted
  7. US 11622970

    BCL-2 inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Expires Apr 6, 2043

    granted
  8. US 11524962

    Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Expires Dec 8, 2042

    granted

Frequently asked questions

What is US patent 10711007?

US 10711007 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jul 14, 2020. Expires Jul 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10711007?

Prelude Therapeutics, Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.

When does US 10711007 expire?

Our index shows an expiration date of Jul 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.